1503TiP A phase II study of cemiplimab plus BNT116 versus cemiplimab alone in first-line treatment of patients with advanced non-small cell lung cancer with PD-L1 expression ≥50%Mark M. Awad, P. Rietschel, F. Seebach et al.|Annals of Oncology|2023Cited by 4
P4.11D.04 A Phase 1/2 Study of REGN7075 (EGFRÃ-CD28) Combined with Cemiplimab (anti-PD-1) In NSCLC: Trial in Progress UpdateM.L. Johnson, Neil H. Segal, Eugenia Girda et al.|Journal of Thoracic Oncology|2024Cited by 0